Fused pentacyclic polyethers
View Patent ↗Disclosed are polycyclic polyether compounds of formula I and pharmaceutical compositions comprising such compounds. wherein R, OR 1 , and R 2 are as defined herein. Also disclosed are methods of regulating mucus clearance in a cell, and methods of treating decreased mucus clearance or mucociliary dysfunction.
1. A method of treating asthma in a subject comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound, or pharmaceutically acceptable salts, esters, amides, or isomers thereof; wherein the compound has the formula:
wherein
R is C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 1 -C 12 alkyl esters, C 1 -C 12 alkyl amides, C 4 -C 12 alkenyl esters, C 1 -C 12 alkylaryl esters, C 4 -C 12 alkenylaryl esters, C 4 -C 12 alkenyl amides, C 1 -C 12 alkoxy, formylC 1 -C 12 alkyl, formylC 2 -C 12 alkenyl, alkanoylC 1 -C 12 alkyl, alkanoylC 2 -C 12 alkenyl, carboxyC 1 -C 12 alkyl, or carboxyC 2 -C 12 alkenyl, wherein the alkyl and alkenyl groups are optionally substituted with 1-6 substituent groups selected from the group consisting of:
C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, aryl, heteroaryl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, C 2 -C 6 alkenyl, OH, aryl esters, cycloalkyl esters, cycloalkenyl esters, and
OR 1 is OH or —O(CO)CH 3 ;
R 2 is —CH═CHCH═CH 2 , —CH 2 -phenyl, or —CH 2 -pyridyl, wherein the phenyl and pyridyl groups are optionally substituted at each substitutable position with a group that is independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, halogen, —CO 2 H, C 1 -C 6 alkoxycarbonyl, —C(O)NH 2 , —C(O)NH(C 1 -C 6 alkyl), or —C(O)N(C 1 -C 6 alkyl) (C 1 -C 6 alkyl).
2. A method of treating a subject who has cystic fibrosis, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound, or pharmaceutically acceptable salts, esters, amides, or isomers thereof; wherein the compound has the formula:
wherein
R is C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 1 -C 12 alkyl esters, C 1 -C 12 alkyl amides, C 4 -C 12 alkenyl esters, C 1 -C 12 alkylaryl esters, C 4 -C 12 alkenylaryl esters, C 4 -C 12 alkenyl amides, C 1 -C 12 alkoxy, formylC 1 -C 12 alkyl, formylC 2 -C 12 alkenyl, alkanoylC 1 -C 12 alkyl, alkanoylC 2 -C 12 alkenyl, carboxyC 1 -C 12 alkyl, or carboxyC 2 -C 12 alkenyl, wherein the alkyl and alkenyl groups are optionally substituted with 1-6 substituent groups selected from the group consisting of:
C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, aryl, heteroaryl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, C 2 -C 6 alkenyl, OH, aryl esters, cycloalkyl esters, cycloalkenyl esters, and
OR 1 is OH or —O(CO)CH 3 ;
R 2 is —CH═CHCH═CH 2 , —CH 2 -phenyl, or —CH 2 -pyridyl, wherein the phenyl and pyridyl groups are optionally substituted at
each substitutable position with a group that is independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, halogen, —CO 2 H, C 1 -C 6 alkoxycarbonyl, —C(O)NH 2 , —C(O)NH(C 1 -C 6 alkyl), or —C(O)N(C 1 -C 6 alkyl) (C 1 -C 6 alkyl).
3. A method of treating brevetoxin or ciguatoxin poisoning, comprising administering a pharmaceutically acceptable amount of a compound, or pharmaceutically acceptable salts, esters, amides, or isomers thereof, to a subject in need of such treatment; wherein the compound has the formula:
wherein
R is C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 1 -C 12 alkyl esters, C 1 -C 12 alkyl amides, C 4 -C 12 alkenyl esters, C 1 -C 12 alkylaryl esters, C 4 -C 12 alkenylaryl esters, C 4 -C 12 alkenyl amides, C 1 -C 12 alkoxy, formylC 1 -C 12 alkyl, formylC 2 -C 12 alkenyl, alkanoylC 1 -C 12 alkyl, alkanoylC 2 -C 12 alkenyl, carboxyC 1 -C 12 alkyl, or carboxyC 2 -C 12 alkenyl, wherein the alkyl and alkenyl groups are optionally substituted with 1-6 substituent groups selected from the group consisting of:
C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, aryl, heteroaryl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, C 2 -C 6 alkenyl, OH, aryl esters, cycloalkyl esters, cycloalkenyl esters, and
OR 1 is OH or —O(CO)CH 3 ;
R 2 is —CH═CHCH═CH 2 , —CH 2 -phenyl, or —CH 2 -pyridyl, wherein the phenyl and pyridyl groups are optionally substituted at
each substitutable position with a group that is independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, halogen, —CO 2 H, C 1 -C 6 alkoxycarbonyl, —C(O)NH 2 , —C(O)NH(C 1 -C 6 alkyl), or —C(O)N(C 1 -C 6 alkyl) (C 1 -C 6 alkyl).
4. The method according to claim 1 , wherein the therapeutically effective amount is administered in a dosage of between about 0.1 pg to about 100 mg per day.
5. The method according to claim 1 , wherein the therapeutically effective amount comprises a dosage of between about 0.1 mg to about 10 mg per day.
6. The method according to claim 2 , wherein the therapeutically effective amount is administered in a dosage of between about 0.1 pg to about 100 mg per day.
7. The method according to claim 2 , wherein the therapeutically effective amount comprises a dosage of between about 0.1 mg to about 10 mg per day.
8. The method according to claim 3 , wherein the therapeutically effective amount is administered in a dosage of between about 0.1 pg to about 100 mg per day.
9. The method according to claim 3 , wherein the therapeutically effective amount comprises a dosage of between about 0.1 mg to about 10 mg per day.